2Zhou XH, Qiao Q, Zethelius B, ct al. Diabetes, prediabetes and cancer mortality [J]. Diabetologia, 2010, 53(9) : 1867-1876.
3Evans JM, Donnelly LA, Emslie-Smiih AM, etal. Metformin and reduced risk of cancer in diabetic patienls [ J ]. BMJ, 2005, 330(7503):1304-1305.
4Libby G, Alessi DR, Donnelly LA, et al. New Users of Metformin Are at Low Risk of Incident Cancer [ J ]. Diabetes Care, 2009, 32(9):1620-1625.
5Currie C J, Poole CD, Gale EA.The influence of glucoselowering therapies on eaneer risk in type 2 diabetes [ J ]. Diabetologia, 2009, 52(9) : 1766-1777.
6Landman GW, Kleefstra N, Van Haleren K J, et al. Metformin associated with lower cancer mortality in type 2 diabetes. ZODIAC-16 [ J ]. Diabetes Care, 2010, 33(11) : 322-326.
7Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer [ J ]. J Clin Oncol, 2009, 27(20) : 3297-3302.
8Bodmer M, Meier C, Krahenbuhl S, et al. Long-term metformin use is associated with decreased risk of breast cancer [ J ]. Diabetes Care, 2010, 33(6) : 1304-1308.
9Li D, Yeung SC, Hassan MM, et al. Anlidiabetic therapies affect risk of pancreatic cancer [ J]. Gastroenterology. 2009, 137(2) : 482-488.
10Hosono K, Endo H, Takahashi H, et al. Metformin suppresses eoloreetal aberrant crypt foei in a short-term clinical trial [ J ]. Cancer Prey Res (Phila), 2010, 3(9) : 1077- 1083.
